Trial reportHypertension research : official journal of the Japanese Society of Hypertension2009
Effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease: subanalysis of the CASE-J Study.
Trial report in Hypertension research : official journal of the Japanese Society of Hypertension, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 57 citations in OpenAlex.
- Microalbuminuria and sRAGE in high-risk hypertensive patients treated with nifedipine/telmisartan combination treatment: a substudy of TALENT.Mediators of inflammation · 2012Trial
- Current use of angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors for hypertension in patients with chronic kidney disease with proteinuria: a cross-sectional study based on real-world data.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- Mortality and hyperkalaemia-associated hospitalisation in patients with chronic kidney disease: comparison of sodium zirconium cyclosilicate and sodium/calcium polystyrene sulfonate.Clinical kidney journal · 2024Article
- Impact of early initiation of renin-angiotensin blockade on renal function and clinical outcomes in patients with hypertensive emergency: a retrospective cohort study.BMC nephrology · 2023Article
- Randomized Controlled Trials on Renin Angiotensin Aldosterone System Inhibitors in Chronic Kidney Disease Stages 3-5: Are They Robust? A Fragility Index Analysis.Journal of clinical medicine · 2022Review
- Renoprotective Effect of a Dipeptidyl Peptidase-4 Inhibitor on Aging Mice.Aging and disease · 2020Article
- PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2020Observational
- Primary and Secondary Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease.Current atherosclerosis reports · 2019Review
- Management of Traditional Cardiovascular Risk Factors in CKD: What Are the Data?American journal of kidney diseases : the official journal of the National Kidney Foundation · 2018Review
- Kidney dysfunction in patients with pulmonary arterial hypertension.Pulmonary circulation · 2017Review
- Key Points of the Japanese Society of Hypertension Guidelines for the Management of Hypertension in 2014.Pulse (Basel, Switzerland) · 2015Review
- Tailored antihypertensive drug therapy prescribed to older women attenuates circulating levels of interleukin-6 and tumor necrosis factor-α.Clinical interventions in aging · 2015Article
- Renal microcirculation and calcium channel subtypes.Current hypertension reviews · 2013Review
- Chapter 3: Blood pressure management in CKD ND patients without diabetes mellitus.Kidney international supplements · 2012Article
- Safety and efficacy of administering the maximal dose of candesartan in renal transplant recipients.Clinical and experimental nephrology · 2011Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We examined the effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease (CKD) using the data from the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial. CKD was defined as proteinuria and/or decreased GFR (<60 ml per min per 1.73 m(2)) at enrollment. Among 2720 subjects with CKD, there were 1376 and 1344 patients in the candesartan and the amlodipine group, respectively. During a 3.2-year follow-up, cardiovascular event rate did not differ in the two groups (7.2% for candesartan and 7.6% for amlodipine). In the subgroup analysis based on the CKD stage, there were no significant differences in the incidence rates of cardiovascular events between the two groups in stages 1+2 and 3 CKD. In stage 4 CKD, however, candesartan reduced the incidence of cardiovascular events (55% risk reduction), particularly of renal events (81% risk reduction), compared with amlodipine. Furthermore, composite cardiovascular events were increased as the CKD stage progressed, and this effect was exaggerated in the presence of proteinuria. Finally, the new onset of diabetes was less in the candesartan-based regimen in stage 3 CKD. In conclusion, candesartan protected hypertensive patients with CKD more potently against renal events, particularly in moderately-to-severely impaired CKD. Furthermore, candesartan prevented a new onset of diabetes in CKD, which would be favorable for the long-term management of CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.